Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema

[1]  T. Craig,et al.  Racial and Ethnic Disparities in the Research and Care of Hereditary Angioedema Patients in the United States. , 2021, The journal of allergy and clinical immunology. In practice.

[2]  J. Bernstein,et al.  Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study , 2021, Allergy.

[3]  W. Lumry,et al.  Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy , 2021, Allergy, Asthma & Clinical Immunology.

[4]  J. Simon,et al.  Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany , 2021, International Archives of Allergy and Immunology.

[5]  T. Craig,et al.  Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report , 2021, Allergy, Asthma & Clinical Immunology.

[6]  E. Aygören‐Pürsün,et al.  Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey , 2021, Orphanet Journal of Rare Diseases.

[7]  W. Lumry,et al.  Hereditary angioedema: Epidemiology and burden of disease. , 2020, Allergy and asthma proceedings.

[8]  J. Bernstein,et al.  US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[9]  T. Zuberbier,et al.  Validation of the Angioedema Control Test (AECT) - a patient reported outcome instrument for assessing angioedema control. , 2020, The journal of allergy and clinical immunology. In practice.

[10]  T. Brown,et al.  Patient-reported burden of hereditary angioedema: findings from a US patient survey. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  T. Zuberbier,et al.  Development of the Angioedema Control Test—A patient‐reported outcome measure that assesses disease control in patients with recurrent angioedema , 2019, Allergy.

[12]  M. Maurer,et al.  Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change , 2019, Health and Quality of Life Outcomes.

[13]  W. Lumry,et al.  Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. , 2019, The journal of allergy and clinical immunology. In practice.

[14]  William H. Yang,et al.  Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. , 2019, The journal of allergy and clinical immunology. In practice.

[15]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[16]  M. Triggiani,et al.  Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.

[17]  M. Triggiani,et al.  Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study , 2018, Allergy.

[18]  W. Aberer,et al.  The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[20]  D. Supina,et al.  Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. , 2017, Allergy and asthma proceedings.

[21]  P. Martus,et al.  The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference , 2016, Allergy.

[22]  H. Longhurst,et al.  The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema , 2016, Clinical Reviews in Allergy & Immunology.

[23]  M. Buchberger,et al.  Nanofiltrated C1‐esterase‐inhibitor in the prophylactic treatment of bradykinin‐mediated angioedema , 2016, Transfusion.

[24]  M. Riedl,et al.  Managing the Female Patient with Hereditary Angioedema , 2016, Women's health.

[25]  M. Maurer,et al.  Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies , 2015, Health and Quality of Life Outcomes.

[26]  P. Martus,et al.  Development, validation, and initial results of the Angioedema Activity Score , 2013, Allergy.

[27]  P. Martus,et al.  Development and construct validation of the angioedema quality of life questionnaire , 2012, Allergy.

[28]  E. Remor,et al.  Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project , 2012, Health and Quality of Life Outcomes.

[29]  D. Cella,et al.  Developing a Valid Patient‐Reported Outcome Measure , 2011, Clinical pharmacology and therapeutics.

[30]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[31]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[32]  O. Chassany,et al.  Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process , 2002 .

[33]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[34]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[35]  D. W. Goodwin.  The Anxiety Disease and How to Overcome It , 1984 .

[36]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[37]  J. Nunnally,et al.  Psychometric Theory , 2020, Encyclopedia of Behavioral Medicine.

[38]  W. Aberer,et al.  Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. , 2016, Journal of investigational allergology & clinical immunology.

[39]  K. Beusterien,et al.  The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. , 2014, Allergy and asthma proceedings.

[40]  A. Sheffer,et al.  The spectrum of chronic angioedema. , 2009, Allergy and asthma proceedings.

[41]  A. Kaplan,et al.  Angioedema. , 2005, Journal of the American Academy of Dermatology.

[42]  K. Schulz,et al.  Hereditary angioedema , 2004, Humangenetik.

[43]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[44]  N. Jersey.,et al.  SENATE OF THE UNITED STATES , 2003 .

[45]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[46]  S. S. Stevens.  Mathematics, measurement, and psychophysics. , 1951 .